Peptide News Digest

#Duravelo-2

6 stories

Duravelo-2 is Bicycle Therapeutics' trial of zelenectide pevedotin (BT8009) plus pembrolizumab as first-line treatment in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Bicycle designed it as a Phase 2/3 study and in 2026 converted it into a randomized Phase 2 trial. Zelenectide pevedotin is a Bicycle toxin conjugate — a Nectin-4-targeting bicyclic peptide linked to the cytotoxin monomethyl auristatin E (MMAE) via a cleavable linker. The drug targets the same antigen as enfortumab vedotin (Padcev) but as a small bicyclic peptide rather than an antibody-drug conjugate, giving it a different tissue-distribution and toxicity profile.

Bicycle confirmed the ASCO 2026 oral presentation slot in April 2026 (Abstract 4516, Monday June 1, 8:30-8:36 AM CT in the GU Cancers track). Interim data were released with the May 21 ASCO abstracts, and the June 1 rapid oral presentation (Abstract 4516, Yohann Loriot) reported that the optimal dose of zelenectide pevedotin plus pembrolizumab matched published standard-of-care response rates with roughly four-fold lower skin reactions and about half the peripheral neuropathy. In the earlier Duravelo-1 trial, zelenectide alone produced a 45% response rate (17 of 38) with an 11.1-month median duration of response in previously treated patients who had not received enfortumab vedotin (ESMO 2024), and zelenectide plus pembrolizumab produced a 65% rate (13 of 20 evaluable, 22 enrolled) in untreated cisplatin-ineligible patients (ASCO 2025).

Stories here cover Duravelo-2 interim data, the broader Bicycle Therapeutics Nectin-4 program (and the separate EphA2 conjugate nuzefatide pevedotin, BT5528), and the urothelial carcinoma treatment landscape. See #bicycle-therapeutics, #zelenectide-pevedotin, and #urothelial-cancer for adjacent threads.

Clinical Trials · View digest

Bicycle Therapeutics Duravelo-2 ASCO 2026 Oral: Optimal-Dose Zelenectide Pevedotin Plus Pembrolizumab Matches Standard-of-Care Response in First-Line Urothelial Cancer With Far Less Skin and Nerve Toxicity

In the June 1 rapid oral session (Abstract 4516, Yohann Loriot), the dose-optimization stage of the randomized Phase 2 Duravelo-2 trial showed the optimal dose of the bicyclic peptide-drug conjugate zelenectide pevedotin (BT8009) plus pembrolizumab produced response rates comparable to published standard-of-care data in previously untreated locally advanced or metastatic urothelial carcinoma, with roughly four-fold lower skin reactions and about half the peripheral neuropathy. The separate Duravelo-1 Phase 1 trial showed median progression-free survival comparable to standard of care in cisplatin-ineligible patients.

Clinical Trials · View digest

Bicycle Therapeutics Duravelo-2 Phase 2 Detailed Data (May 22): 65% ORR (17/26) and 58% BICR-Confirmed ORR (15/26) at 27-Week Cutoff for Zelenectide Pevedotin + Pembrolizumab in 1L Urothelial Cancer

Bicycle Therapeutics' formal post-ASCO 2026 press release Friday morning specified the headline Phase 2 numbers from yesterday's abstract release. In the Duravelo-2 combination cohort, the optimal zelenectide dose plus pembrolizumab 200 mg every three weeks produced 65% ORR (17/26 evaluable patients) regardless of confirmation, with 58% BICR-confirmed ORR (15/26) at the 27-week cutoff in previously untreated locally advanced or metastatic urothelial cancer. An additional confirmed BICR response observed after the cutoff would bring the rate to 62%. The trial tested two dose schedules: 5 mg/m² weekly and 6 mg/m² two-weeks-on-one-week-off; the optimal dose moves forward. Treatment retention was high and dose-limiting adverse events limited. The 65% ORR is similar to the 65% (13/20) seen with the same combination in untreated cisplatin-ineligible patients in the earlier Duravelo-1 trial, though comparisons across trials are limited.

Clinical Trials · View digest

Bicycle Therapeutics Duravelo-2 ASCO 2026 Data (May 21): Zelenectide Pevedotin + Pembrolizumab in 1L Urothelial — Oral Presentation Monday June 1, Abstract 4516

Bicycle Therapeutics released Duravelo-2 Phase 2 interim analysis data at ASCO 2026 — zelenectide pevedotin (BT8009, a Nectin-4-targeting bicyclic peptide-MMAE conjugate) plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer. The full data presentation is scheduled for Monday June 1, 8:30-8:36 AM CT in the GU Cancers oral session (Abstract 4516). In the earlier Duravelo-1 trial, zelenectide plus pembrolizumab produced a 65% response rate (13 of 20 evaluable patients) in untreated cisplatin-ineligible patients (ASCO 2025). Bicycle's five ASCO abstracts, all on zelenectide, pair the Duravelo-2 oral with four posters: Duravelo-2 in previously treated patients, two Duravelo-1 updates, and a dose-optimization analysis.

Clinical Trials · View digest

Bicycle Therapeutics Duravelo-2 Oral Abstract Confirmed for ASCO 2026 June 1 (8:30 a.m. CT): Zelenectide Pevedotin (BT8009) + Pembrolizumab Interim Analysis in 1L Locally Advanced/Metastatic Urothelial Cancer

Bicycle Therapeutics confirmed the Duravelo-2 oral abstract presentation slot at the ASCO 2026 Annual Meeting on Monday, June 1, 8:30–8:36 a.m. CT. The abstract reports interim analysis results from Duravelo-2, a randomized Phase 2 trial of zelenectide pevedotin (BT8009) plus pembrolizumab as first-line treatment for previously untreated locally advanced or metastatic urothelial carcinoma. Zelenectide pevedotin is Bicycle's Nectin-4-targeting bicyclic peptide-drug conjugate, a separate program from the EphA2-targeting nuzefatide pevedotin (BT5528) covered earlier on this site. Bicycle's April 30 first-quarter report listed $559.5M in cash and a runway into 2030.

Industry · View digest

Bicycle Therapeutics Q1 2026 (April 30): $559.5M Cash, Runway Into 2030, Duravelo-2 Becomes a Randomized Phase 2 Trial

Bicycle Therapeutics reported a first-quarter net loss of $60.8M ($0.87 per share) on April 30, with R&D expenses of $48.9M and $559.5M in cash and equivalents at March 31, which it expects to fund operations into 2030. After a first-quarter reprioritization, Bicycle is converting Duravelo-2, its trial of zelenectide pevedotin (BT8009) plus pembrolizumab in metastatic urothelial cancer, into a randomized Phase 2 trial, with initial dose-selection data set for ASCO 2026. It is shifting resources to nuzefatide pevedotin (BT5528), whose Phase 2 trial in recurrent pancreatic cancer dosed its first patient in April, and to radiopharmaceuticals and imaging agents.

Clinical Trials · View digest

Bicycle Therapeutics Sets ASCO 2026 Program: One Oral and Four Posters on Zelenectide Pevedotin (BT8009) in Urothelial Cancer

Bicycle Therapeutics will present five abstracts at the 2026 ASCO Annual Meeting (May 29-June 2 in Chicago), all on zelenectide pevedotin (BT8009), its Nectin-4-targeting bicyclic peptide-drug conjugate. Yohann Loriot will give interim Duravelo-2 results with pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer in a June 1 rapid oral session (Abstract 4516). Four May 31 posters cover Duravelo-2 in previously treated patients, two Duravelo-1 updates, and dose optimization.